

REMARKS

Claims 1, 4-7, 16, and 26-27 are pending in the present application. Claims 1, 4, 5, 6, 7, and 16 have been amended as described elsewhere herein to increase clarity. The amendments to the claims are supported by the originally-filed claims and specification including, for example lines 29-30 of page 15, line 34 of page 16 through line 2 of page 17, and lines 15-18 of page 17 of the specification. No new matter has been added by way of amendment. Reconsideration and withdrawal of the rejection of claims are respectfully requested.

The Rejection Under 35 U.S.C. §112, Second Paragraph, Should be Withdrawn

Claims 1, 4-7, and 16 have been rejected under 35 U.S.C. §112, second paragraph, on the grounds that the scope of the terms "heteroaryl," "heteroarylene," "heterocyclic," and "heterocyclyl" are indefinite. Applicants respectfully disagree with the rejection on the grounds that the scope of these terms would be clear to one of skill in the art when read in light of the supporting specification. Nevertheless, in order to expedite prosecution, claim 1 has been amended to incorporate the examples of these groups which are provided in the specification, thereby overcoming the rejection.

The Office Action also states that when a moiety is modified by a substitution, the possible substituents must be specified. Applicants believe that previously presented claims meet this requirement. Claims 4-7 depend from claim 1, and claim 1 provided a list of substituents for each group where substitution is encompassed. Nevertheless, in order to expedite prosecution, claims 4-7 have been amended to again specify the list of possible substituents.


In view of the above amendments, all grounds for rejection under 35 U.S.C. §112, second paragraph, have been obviated or overcome. Reconsideration and withdrawal of the rejection are therefore respectfully requested.

CONCLUSION

It is believed that the current application is now in condition for allowance. Early notice to this effect is solicited. If, in the opinion of the Examiner, an interview would expedite prosecution, the Examiner is invited to call the undersigned.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: 12/23/2008
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988